Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report released on Wednesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of EGRX stock opened at $1.96 on Wednesday. Eagle Pharmaceuticals has a fifty-two week low of $1.50 and a fifty-two week high of $2.00. The stock’s 50-day simple moving average is $1.41 and its 200-day simple moving average is $0.98.

Institutional Investors Weigh In On Eagle Pharmaceuticals

A hedge fund recently bought a new stake in Eagle Pharmaceuticals stock. Jane Street Group LLC bought a new position in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 25,837 shares of the specialty pharmaceutical company’s stock, valued at approximately $96,000. Jane Street Group LLC owned 0.20% of Eagle Pharmaceuticals as of its most recent SEC filing. 85.36% of the stock is currently owned by institutional investors and hedge funds.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.